Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Ocular Therapeutix: Q1 Earnings Insights
12:43pm, Friday, 08'th May 2020
Shares of Ocular Therapeutix (NASDAQ:OCUL) were unchanged in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were up 8.89% year over year to ($0.41), whic
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
12:25pm, Friday, 08'th May 2020
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -2.50% and -1.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix™ Reports First Quarter 2020 Financial Results and Business Update
11:00am, Friday, 08'th May 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda
12:00am, Friday, 08'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 7)
• Acceleron Pharma Inc (...
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Ocular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
04:30pm, Friday, 01'st May 2020
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix™ To Report First Quarter 2020 Financial Results
12:00pm, Thursday, 30'th Apr 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
Ocular Therapeutix (NASDAQ:OCUL) Rating Increased to Buy at BidaskClub
09:24am, Thursday, 30'th Apr 2020
Ocular Therapeutix (NASDAQ:OCUL) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, BidA
BBBY, DVAX among premarket gainers
01:22pm, Tuesday, 28'th Apr 2020
Broadwind Energy (NASDAQ:BWEN) +60%. on $19M order.TrovaGene (NASDAQ:TROV) +44% on new positive results from its ongoing Phase 1b/2 clinical trial of onvansertib in combination with FOLFIRI and Avast
34 Stocks Moving in Tuesday's Pre-Market Session
11:16am, Tuesday, 28'th Apr 2020
Gainers
Document Security Systems, Inc. (NYSE: DSS) shares rose 43.8% to $0.43 in pre-market trading after the company reported completion of required independent valuation,...
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
-$0.40 Earnings Per Share Expected for Ocular Therapeutix Inc (NASDAQ:OCUL) This Quarter
09:52am, Tuesday, 28'th Apr 2020
Wall Street analysts predict that Ocular Therapeutix Inc (NASDAQ:OCUL) will announce earnings per share of ($0.40) for the current fiscal quarter, according to Zacks. Four analysts have provided estim
Ocular Therapeutix™ Provides Business Update and Response to COVID-19 Global Pandemic
12:00pm, Monday, 13'th Apr 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
